Abstract
AAV-mediated gene therapy (AAVGT) is a novel treatment offering curative effects for several genetic diseases. The high upfront cost of AAVGT and the uncertainty around durability of its effectiveness are posing challenges for health economists. The ISPOR taskforce compiled a list of special considerations, including exploring different discounting rates (DRs). We examined the impact of different DRs when comparing AAVGT to alternative treatments in persons with hemophilia A.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
